ClinicoEconomics and Outcomes Research

Top Research Topics at ClinicoEconomics and Outcomes Research?

The journal is mainly concerned with subjects like Internal medicine, Health care, Emergency medicine, Pediatrics and Indirect costs. The study on Internal medicine presented in it intersects with subjects under the field of Oncology. The concepts on Health care presented in it can also apply to other research fields, including Psychological intervention, Environmental health, Intensive care medicine, Disease and Medical prescription.

ClinicoEconomics and Outcomes Research links adjacent topics like Intensive care medicine with Alternative medicine. The journal focuses on Indirect costs research which is adjacent to topics in Total cost.

• Internal medicine (29.68%)
• Health care (27.23%)
• Emergency medicine (14.27%)

What are the most cited papers published in the journal?

• The clinical and economic burden of chronic obstructive pulmonary disease in the USA. (241 citations)
• The costs of traumatic brain injury: a literature review. (168 citations)
• Epidemiology of falls and osteoporotic fractures: a systematic review (117 citations)

Research areas of the most cited articles at ClinicoEconomics and Outcomes Research:

The published articles cover a variety of subjects, including Health care, Pediatrics, Emergency medicine, Indirect costs and Internal medicine. The journal publications address concerns in Pediatrics which are intertwined with other disciplines, such as Quality of life, Intensive care medicine, Hiv treatment, Antiretroviral therapy and Cohort. The published articles discuss concepts in Disease under Internal medicine and how they intertwine with disciplines like Escitalopram.

What topics the last edition of the journal is best known for?

• Internal medicine
• Surgery
• Disease

The previous edition focused in particular on these issues:

ClinicoEconomics and Outcomes Research aims to foster the development of research in Internal medicine, Health care, Emergency medicine, Cohort and Quality of life. The presented Internal medicine study covers related areas such as Inflammatory bowel disease and also touches on topics like In patient. The studies on Health care discussed can also contribute to research in the domains of Psychological intervention, Quality of life (healthcare), Systematic review, Retrospective cohort study and Mental health.

Retrospective cohort study research featured in ClinicoEconomics and Outcomes Research incorporates concerns from various other topics such as Observational study and Disease. The presented Emergency medicine research provided insight into the related

• Budget impact, which have a strong connection to Adverse effect,
• Cost-effectiveness analysis which intersects with area such as Sensitivity analyses.. Topics in Quality of life explored in it were investigated in conjunction with research in Diabetes mellitus, Glycemic, Type 2 Diabetes Mellitus and Economic evaluation.

The most cited articles from the last journal are:

• Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database. (2 citations)
• Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy. (2 citations)
• Implementation Status of Health Management Information System in Hospitals of South West Shoa Zone, Oromia, Central Ethiopia. (2 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in ClinicoEconomics and Outcomes Research (based on the number of publications) are:

• Luca Degli Esposti (15 papers) published 1 paper at the last edition,
• Sergio Di Matteo (14 papers) published 1 paper at the last edition the same number as at the previous edition,
• Stefano Buda (12 papers) absent at the last edition,
• Machaon Bonafede (11 papers) published 1 paper at the last edition,
• Stefan Walzer (10 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in ClinicoEconomics and Outcomes Research (based on the number of publications) are:

• Pfizer (43 papers) published 6 papers at the last edition, 2 more than at the previous edition,
• Eli Lilly and Company (24 papers) published 1 paper at the last edition, 1 less than at the previous edition,
• Bristol-Myers Squibb (17 papers) published 1 paper at the last edition, 2 less than at the previous edition,
• Novartis (16 papers) absent at the last edition,
• University of Pavia (15 papers) published 1 paper at the last edition the same number as at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 26.83% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 28.33% were posted by at least one author from the top 10 institutions publishing in the journal. Another 8.33% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 11.67% of all publications and 51.67% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in Healthcare Research

For those passionate about ClinicoEconomics and Outcomes Research, there are many career opportunities available in the healthcare research field. Whether your interests lean towards internal medicine, paediatrics, emergency medicine, Indirect costs or more, the industry has something to offer. To excel in these positions, certain qualifications and licensure may be required. For instance, if you are based in New York and considering a nursing career in research, familiarize yourself thoroughly with the new york nursing license requirements. It's important to note those pursuing a career in research may also need additional education or certifications specific to research methodologies, data analysis, and clinical practices. Choosing a career in healthcare research not only offers various learning opportunities but also the chance to contribute positively to the healthcare system and patient lives. The field is constantly evolving, providing endless possibilities for research studies, breakthroughs, and advancements. Utilizing your skills in this ever-growing field can lead to a rewarding and impactful career.